Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0476089 (endometrial cancer)
 11,379 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of high doses of medroxyprogesterone acetate (MPA) on liver metabolism were investigated by determining the plasma antipyrine clearance rates for a group of 11 patients with endometrial cancer both before and during use of MPA in therapy. MPA dosage was 250 mg, intramuscularly, for 6 days. The antipyrine half-life was prolonged in 4 patients. MPA treatment had an inducing effect on antipyrine metabolism; the plasma half-life of the drug was shortened and apparent clearance rate increased; however, no change occurred in the apparent volume of distribution of the drug. Significant decreases in bilirubin were also seen (P .01), but no other liver function tests showed significant differences. When the patients were divided into 2 groups according to age over or under 60 years, there was a significant difference (P .05), with the younger group having a half-life of 8.1 hours and the older group evincing a half-life of 13.6. These half-lives were reduced by MPA treatment to 7.5 and 11 hours, respectively. The results indicate that MPA therapy has an inducing effect on hepatic enzyme activity and antipyrine metabolism.
Biomedicine 1979 Sep
PMID:Antipyrine metabolism and liver function in patients treated with high-dose medroxyprogesterone. 50 96

A previous leading article on estrogen treatment and endometrial cancer is criticized for not showing scientific appraisal. There was a misunderstanding of the case-control approach. The reasoning is invalid because it is incomplete and misleading. There are 2 previous contradictory case-control studies in which no relationship was found between estrogens and endometrial cancer. Clinical events can create prescribor bias and produce detector bias to show a fallacious relationship. An undetected endometrial cancer may already have been present when the estrogen was prescribed for bleeding, or estrogen given for postmenopausal symptoms may have provoked bleeding that led to diagnostic curettage. Estrogen's alleged carcinogenicity awaits further scientific investigation.
Br Med J 1977 Sep 17
PMID:Oestrogen treatment and endometrial carcinoma. 56 13

Due to adverse publicity alleging an increased risk of endometrial cancer with estrogen therapy, a prospective study was begun in 1976 to determine the incidence of this disease in postmenopausal women. During 5,025 patient-years of observation in 1976-1977, 6 adenocarcinomas of the endometrium were diagnosed for an incidence of 1.2:1,000 postmenopausal women per year. No endometrial malignancies were detected in 2,552 patient years of therapy with estrogens and progestogens. In 1,028 patient-years of observation where estrogens only was the therapy, there were 3 endometrial cancers for an incidence of 2.9:1,000. Adenocarcinoma of the endometrium was found in 2 of the untreated group, which gave an incidence of 3.0:1,000. The sixth endometrial cancer occurred in a patient using estrogen vaginal cream. During this same period, 139 perimenopausal and postmenopausal women were treated with progestogens for endometrial hyperplasia. The hyperplasia was reversed to normal endometrium in 133 patients (95.7%). Hyperplasia is a precancerous lesion and should be treated with either progestogens or hysterectomy. All postmenopausal women with a uterus should be given the Progestogen Challenge Test and the progestogen continued each month as long as bleeding follows. These methods will prevent most endometrial cancers.
Maturitas 1978 Sep
PMID:The prevention of endometrial cancer in postmenopausal women with progestogens. 75 56

Six cases of spigelian hernia are reported, including three unusual ones: (1) the presence of an acutely inflamed appendix in the hernial sac; (2) a patient with multiple associated hernias; and (3) a woman with a strangulated spigelian hernia occurring with endometrial carcinoma. The anatomy, etiology, clinical features and management of these hernias are discussed.
Am Surg 1977 Sep
PMID:Spigelian hernia. 90 Jun 52

The existence of precancerous lesions of the endometrium is well established, but differences in terminology and difficulties in the interpretation of published studies have complicated quantitation of the malignant potential of the descibed subtypes. Clinical investigations, cellular studies, chromosome and DNA analyses, and animal experiments suggest that the malignant potential of cystic hyperplasia is low in contrast to that of the more complex types of hyperplasia. The significance of atypical secretory hyperplasia, squamous metaplasia, and endometrial polyps in the evolution of endometrial cancer has not been investigated adequately. Artifactual crowding of glands due to fragmentation and benign processes such as the epithelial regeneration in late menstrual endometrium and the Arias-Stella reaction should not be confused with precancerous changes. A classification of precancerous lesions is presented and the need for adoption of a uniform terminology for future investigations and communication with gynecologists is emphasized.
Hum Pathol 1977 Sep
PMID:Precancerous lesions of the endometrium. 90 43

The serum enzymatic activities of cystine aminopeptidase and leucine aminopeptidase were measured in a group of 113 patients of whom 90 had benign uterine or ovarian tumors, and 23 had cancer of the endometrium or ovary. Thirty healthy nonpregnant women and 260 women at different stages of normal pregnancy served as control groups. The presence of pregnancy-specific enzymes in women with uterine or ovarian tumors showed once again that similar processes occur during pregnancy and malignancy. When ovarian or uterine malignancy is suspected on clinical examination, determination of the activities of these enzymes in serum may be of diagnostic value.
Isr J Med Sci 1977 Sep
PMID:Serum cystine aminopeptidase and leucine aminopeptidase activity in women with benign and malignant uterine and ovarian tumors. 92 62

A logistic regression model is used to study the association between a dichotomous exposure variable and a disease. The method takes into account factors that may confound the association and leads to a quantitative study of the influence of factors which are related to the strength of the association. Special results are given for matched pair data. A case-control study relating post-menopausal estrogen use and endometrial cancer provides illustration.
Biometrics 1976 Sep
PMID:Use of the logistic model in retrospective studies. 96 73

In a retrospective study characteristics of 729 climacteric and postmenopausal women with hyperplasia and adenocarcinoma of the endometrium are compared with those of 82 women with atrophic endometrium and 96 women with carcinoma of the cervix. In a prospective study 225 women with glandular-cystic, adenomatous and atypical hyperplasia of the endometrium have been checked by a control-curettage within a period of two months until four years following the first diagnosis. Low parity, disturbances of menstruation with anovulatoric bleedings during fertility period, adipositas, hypertension and diabetes mellitus in climacteric and postmenopausal women indicate a high risk of carcinoma of the endometrium. Hyperplasias of the endometrium in climacteric women cannot be considered as precursors of corpus carcinoma. They are the result of a temporary hormonal dysfunction. Prophylactic hysterectomy, however, should be performed, if adenomatous or atypical hyperplasia appears in older postmenopausal women with the indicators of high risk of endometriumcarcinoma as mentioned above.
Fortschr Med 1976 Sep 23
PMID:[Epidemiology of endometrial hyperplasia and adenocarcinoma]. 97 98

The published data for overall cancer incidence for the registries of Birmingham (UK) and Connecticut (US) show remarkable similarity for men but diverge for women. The incidence of cancer of the endometrium, ovary and breast in Connecticut is higher than in Birmingham, and in each case the menopausal dislocation in the age-specific incidence plot of the Birmingham data is obscured in that for Connecticut. For endometrial cancer, the difference correlates with differences in the two countries in the use of oestrogen replacement therapy, recently implicated in the aetiology of endometrial cancer. The similarity in the pattern for ovarian and breast cancer, and the changing pattern of breast cancer incidence in Birmingham suggest a similar aetiological effect.
Int J Epidemiol 1976 Sep
PMID:Age-specific incidence of cancer of the endometrium, ovary and breast in the United Kingdom and the United States. 99 30

17 beta-Hydroxysteroid dehydrogenase (17HSD) and estrogen (ER) and progestin (PR) receptors were analyzed immunohistochemically in tissue specimens of 66 patients with endometrial adenocarcinoma. Plasma steroid concentrations were correlated to immunohistochemical data. 17HSD was detected in 48% of the specimens and was stained in the cytoplasm of epithelial cells. The tissues were characterized by a heterogeneous staining pattern for 17HSD. In some patients, intensively stained epithelial cell clusters were seen, indicating that local factors were responsible for the expression of the protein. Poorly differentiated adenocarcinoma specimens tended to have no 17HSD more frequently than did well or moderately differentiated tissues. ER and PR were detectable in 24% and 28% of patients, respectively, and were localized in the nuclei of epithelial and stromal cells. There was a significant correlation between 17HSD and PR staining and an inverse correlation between plasma progesterone concentrations and 17HSD staining. This is contrary to the data obtained with normal endometrium. The main reason for this inverse relation between endometrial 17HSD staining and plasma progesterone concentrations was that, in some postmenopausal patients with low plasma progesterone concentrations, intense staining for 17HSD was detectable in the endometrial carcinoma specimens. This indicates a major difference in the regulation of 17HSD expression in endometrial adenocarcinomas, compared with normal tissues of premenopausal women.
Cancer 1992 Sep 15
PMID:Immunohistochemical study of the human 17 beta-hydroxysteroid dehydrogenase and steroid receptors in endometrial adenocarcinoma. 132 75


<< Previous 1 2 3 4 5 6 7 8 9 10 Next >>